Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Depressive Disorder, Major, Inflammation
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 145
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Conditions: Fractures, Bone, Opioid Use, Trauma
Interventions: Narcotic pain medication, Nonnarcotic pain medications; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Alzheimer Disease
Interventions: Optional Medication Washout, Survey; Other
Lead sponsor: Adams Clinical; Network
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Watertown, Massachusetts • New York, New York

Conditions: Hip Surgery, Juvenile; Scoliosis, Kyphosis, Pectus Surgery, Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis;Congenital, Spondylolisthesis
Interventions: Fast-Dissolve Melatonin Pill, Fast-Dissolve Placebo Pill; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Malignant Testicular Germ Cell Tumor
Interventions: Clinical Stage I Disease, Clinical Stage I with relapse, CSII Disease; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Male only
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 2 more

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement; Procedure · Drug · Dietary Supplement
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Solid Tumor
Interventions: TL118 Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Glendale, California • Dallas, Texas • Houston, Texas + 1 more

Conditions: Hormone-refractory Prostate Cancer
Interventions: Androgen receptor signaling inhibitor (ARSI), Docetaxel, VIR-5500; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • Orange, California + 6 more

Conditions: Epilepsy
Interventions: Tripolar electroencephalography; Device
Lead sponsor: CREmedical; Industry
Eligibility: 6 Years and older
Enrollment: 90 participants
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona • Boston, Massachusetts

Conditions: Breast Cancer, Lymphoma
Interventions: PARASYM neuromodulation device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Tulsa, Oklahoma

Conditions: Glioma
Interventions: BI 764532; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Orange, California • Nashville, Tennessee

Conditions: Arthroplasty Complications, Fragility Fracture, Osteoporosis
Interventions: Surgeon-Initiated Bone Health Referral Pathway; Combination Product
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Multiple Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Elranatamab, Lenalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 34
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 21 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: COPD Wellness, COPD Wellness Plus+, Usual Care; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 90 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Myelofibrosis
Interventions: Pegylated interferon alpha2a; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Kidney Stones, Recurrent Calcium-oxalate Kidney Stones, Urinary Stone Disease / Nephrolithiasis
Interventions: Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101), Vancomycin and neomycin antibiotic pretreatment; Drug
Lead sponsor: Joshua Stern; Other
Eligibility: 18 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Park City, Utah

Conditions: Cancer, Chronic Kidney Disease, Diabetes, Metabolic Disorders, Normal Physiology
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dizziness, Fall Prevention, Fall Related Injury Risk, Hearing Loss, Imbalance, Speech Intelligibility, Vertigo
Interventions: Hearing aids equipped with motion sensing abilities; Device
Lead sponsor: Stanford University; Other
Eligibility: 55 Years and older
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Ulcerative Colitis
Interventions: Etrasimod; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 22
States / cities: Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 9 more

Conditions: Non-small Cell Lung Cancer
Interventions: Sutetinib Maleate Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 8
States / cities: Glendale, California • Washington D.C., District of Columbia • Athens, Georgia + 5 more

Conditions: Breast Cancer, Neuroendocrine Tumors, Prostate Cancer
Interventions: Total-body PET imaging; Diagnostic Test
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cataract, Compliance, Medication, Compliance, Patient, Satisfaction, Patient, Surgery
Interventions: Dropless Regimen, Standard Regimen; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreas Cancer
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Tulsa, Oklahoma

Search by objective public record fields.

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures

Triage Survey for Neurology Research Eligibility

Studying Melatonin and Recovery in Teens

MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD

AlloHCT With PegINFa for Myelofibrosis

Fecal Microbiota Transplantation in Kidney Stone Patients

A Natural History Study of Metabolic Sizing in Health and Disease

Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population

ctDNA Assay in Patients With Resectable Pancreatic Cancer